Clinical Trials Logo

Bone Marrow Neoplasms clinical trials

View clinical trials related to Bone Marrow Neoplasms.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05488717 Completed - Mental Health Clinical Trials

The Effect of Art-Based Mandala on Mental Health in Bone Marrow Transplant Patients

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

According to the World Health Organization (WHO), health is not only a state of complete well-being in terms of illness and disability, but also physical mental and social well-being. Mental health, on the other hand, is a state of goodness in which the individual is aware of his own abilities, copes with the normal tensions of life, can work productively and efficiently and contributes to the society in which he lives. It has been shown in many studies that mental health problems negatively affect the existing disease process. For example, research shows an association between depression and anxiety and cardiovascular and cerebrovascular diseases . In the New York Health Survey, 10,000 individuals representing 33 communities were surveyed by phone; it was found that the general health status of people who reported significant emotional distress was three times worse than those who did not report it . Realizing that mental health is more than just a disease will guide individuals and caregivers. Developing a more comprehensive clinical approach by focusing on a person's healthy, strengths, abilities and personal efforts is important in strengthening mental health. Applications for strengthening mental health include improving nutrition and housing conditions, increasing access to education, strengthening social networks, creating support environments. In the acceptance and stability therapy study of Bash and Dirik with cancer, it was determined that the negative psychological symptoms of the patients decreased and their expectations of life and quality of life increased. In another study , it was determined that the spiritual support practices provided to 150 individuals with breast cancer positively affected the state of spiritual, psychological and physical well-being. Cancer is a life-threatening disease that is common all over the world and affects the individual both physically and psychologically. Hematologic cancers are caused by bone marrow, the place of production of blood, and include diseases such as acute-chronic leukemias and multiple myelomas. Chemotherapy, radiotherapy, surgical methods in the treatment of hematologic cancers; hormonal and biological treatment and bone marrow transplantation (CIS) may be preferred. Among the applications aimed at strengthening mental health are art-based applications (music therapy, applications for visual arts-painting, painting, mandala, clay works, etc.), collage, carving, sculpture, poetry therapy, etc.) as subheadings for the creation of supportive environments. we come across it. When the literature is examined, it is stated that the participation of individuals with art-based applications increases the adaptation process, helps them to find the meaning of life, increases their awareness of cancer and their life, is better adapted to disease and treatment, their emotional expression is more effective, and the state of spiritual and psychological well-being improves positively . Art-based applications provide a significant reduction in anxiety levels in adult cancer patients ; health-related quality of life . In other studies with cancer patients, it was found that art therapy practices reduce the feeling of anxiety and depression and cause a significant increase in health-related quality of life, patients feel more valued and strong, self-esteem increases, interpersonal relationships develop and they are more social .

NCT ID: NCT05251168 Completed - Lymphoma Clinical Trials

PET Guided Bone Marrow Biopsy vs Trephine Bone Marrow Biopsy

Start date: January 1, 2017
Phase:
Study type: Observational

Newly diagnosed lymphoma patients were recruited for FDG PET/CT and PET/CT guided bone marrow biopsy. All the patients also underwent routine bone marrow sampling from the posterior superior iliac spine.

NCT ID: NCT03640572 Completed - Colorectal Cancer Clinical Trials

Disseminated Tumour Cells (DTC) in Left Sided Colorectal Cancer (LSCC).

Start date: June 1, 2007
Phase:
Study type: Observational

Two metaanalyses of studies on the prognostic significance of circulating cancer cells in colorectal cancer indicated, that the presence of circulating tumour cells (CTC) in the peripheral blood is the negative prognostic factor. However there is no sufficient evidence that disseminated tumour cells (DTC) in the bone marrow of the colorectal cancer patients influence the prognosis. There is the evidence that right-sided and left- sided cancers may have different biology and different prognosis. Therefore in this study the investigators concentrated on the left colon and rectum locations with the locally advanced cancer being the main area of interest. The aim of this study was to analyse the relation of DTC with the tumor characteristics, cancer progression and survival in left sided colorectal cancer.

NCT ID: NCT00436059 Completed - Multiple Myeloma Clinical Trials

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

Start date: February 2007
Phase: Phase 2
Study type: Interventional

The primary objective of the the study is to investigate the changes in bone remodeling during Velcade treatment.

NCT ID: NCT00421213 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

NCT ID: NCT00113893 Completed - Clinical trials for Myelodysplastic Syndromes

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of oral SCIO-469 in patients with myelodysplastic syndromes. SCIO-469 belongs to a new class of treatments that inhibit expression and activity of cytokines that play a role in the progression of MDS.